Abstract:The inward rectifier potassium (Kir) channel Kir4.1 (KCNJ10) carries out important physiologic roles in epithelial cells of the kidney, astrocytes in the central nervous system, and stria vascularis of the inner ear. Loss-of-function mutations in KCNJ10 lead to EAST/SeSAME syndrome, which is characterized by epilepsy, ataxia, renal salt wasting, and sensorineural deafness. Although genetic approaches have been indispensable for establishing the importance of Kir4.1 in the normal function of these tissues, the availability of pharmacological tools for acutely manipulating the activity of Kir4.1 in genetically normal animals has been lacking. We therefore carried out a high-throughput screen of 76,575 compounds from the Vanderbilt Institute of Chemical Biology library for small-molecule modulators of Kir4.1. The most potent inhibitor identified was 2-(2-bromo-4-isopropylphenoxy)-N-(2,2,6,6-tetramethylpiperidin-4-yl)acetamide (VU0134992). In whole-cell patch-clamp electrophysiology experiments, VU0134992 inhibits Kir4.1 with an IC50 value of 0.97 µM and is 9-fold selective for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC50 = 9 µM) at -120 mV. In thallium (Tl+) flux assays, VU0134992 is greater than 30-fold selective for Kir4.1 over Kir1.1, Kir2.1, and Kir2.2; is weakly active toward Kir2.3, Kir6.2/SUR1, and Kir7.1; and is equally active toward Kir3.1/3.2, Kir3.1/3.4, and Kir4.2. This potency and selectivity profile is superior to Kir4.1 inhibitors amitriptyline, nortriptyline, and fluoxetine. Medicinal chemistry identified components of VU0134992 that are critical for inhibiting Kir4.1. Patch-clamp electrophysiology, molecular modeling, and site-directed mutagenesis identified pore-lining glutamate 158 and isoleucine 159 as critical residues for block of the channel. VU0134992 displayed a large free unbound fraction (fu) in rat plasma (fu = 0.213). Consistent with the known role of Kir4.1 in renal function, oral dosing of VU0134992 led to a dose-dependent diuresis, natriuresis, and kaliuresis in rats. Thus, VU0134992 represents the first in vivo active tool compound for probing the therapeutic potential of Kir4.1 as a novel diuretic target for the treatment of hypertension.

Electrophysiological characterization of 14-benzoyltalatisamine, a selective blocker of the delayed rectifier K+ channel found in virtual screening.

Discovery of Talatisamine As a Novel Specific Blocker for the Delayed Rectifier K+ Channels in Rat Hippocampal Neurons

Electrophysiological characterization of a novel Kv channel blocker N , N ′-[oxy bis (2,1-ethanediyloxy-2,1-ethanediyl)] bis (4-methyl)-benzenesulfonamide found in virtual screening

Electrophysiological characterization of a novel Kv channel blocker N, N|[prime]|-[oxybis(2,1-ethanediyloxy-2,1-ethanediyl)]bis(4-methyl)-benzenesulfonamide found in virtual screening

Distinct mechanisms of inhibition of Kv2 potassium channels by tetraethylammonium and RY785

Structure-based discovery of potassium channel blockers from natural products: virtual screening and electrophysiological assay testing.

The newly identified K + channel blocker talatisamine attenuates beta-amyloid oligomers induced neurotoxicity in cultured cortical neurons

Mechanisms Underlying the Antiarrhythmic Action of Compound ALM-802

Molecular Determinants for the High-Affinity Blockade of Human Ether-à-go-go-Related Gene K+ Channel by Tolterodine

Interaction between tetraethylammonium and permeant cations at the inactivation gate of the HERG potassium channel

Discovery, Characterization, and Effects on Renal Fluid and Electrolyte Excretion of the Kir4.1 Potassium Channel Pore Blocker, VU0134992

Molecular determinants of KCNQ1 channel block by a benzodiazepine.

Modest CaV1.342-selective inhibition by compound 8 is β-subunit dependent.

Inhibition by Bis(7)-Tacrine of Native Delayed Rectifier and KV1.2 Encoded Potassium Channels

Electrophysiologic Effects of SB-237376: a New Antiarrhythmic Compound with Dual Potassium and Calcium Channel Blocking Action.

Structure‐Based Virtual Screening and Electrophysiological Evaluation of New Chemotypes of Kv1.5 Channel Blockers

Modest Ca V 1.3 42 -selective inhibition by compound 8 is β-subunit dependent

The membrane permeable calcium chelator BAPTA-AM directly blocks human ether a-go-go-related gene potassium channels stably expressed in HEK 293 cells

Modeling the Binding Modes of Kv1.5 Potassium Channel and Blockers.

Use of tetraethylammonium (TEA) and Tris loading for blocking TRPM7 channels in intact cells

At1r-Based Virtual Screening Model for Bioactive Components from Traditional Chinese Medicines and Its Mechanism Study